| Document |
Document Title |
|
WO/2007/048974 |
The invention concerns novel glycoside oligomers, monomers useful for preparing same, as well as a method for preparing such oligomers and in particular D-glucosamine and N-acétyl-D-glucosamine heterooligomers, enabling the size, the de...
|
|
WO/2007/045469 |
The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination...
|
|
WO/2007/042469 |
The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the ...
|
|
WO/2007/042470 |
The present invention relates compounds of the formula I : oligosaccharide-spacer-GpIIb/IIIa antagonist I, wherein the oligosaccharide is a negatively charged pentasaccharide residue of the structure (I), the charge being compensated by ...
|
|
WO/2007/042469 |
The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the ...
|
|
WO/2007/041514 |
A process is described for selectively extracting cocoa procyanidins from an aqueous mixture of cocoa polyphenols by using a particular sequence of solvents to extract selected procyanidin monomers and/or oligomers. The solvents are n-bu...
|
|
WO/2007/038829 |
The invention provides a method of identifying biologically active compounds comprising: (a) designing a first library of compounds of formula (1) to scan molecular diversity wherein each compound of the library has at least two pharmaco...
|
|
WO/2007/033292 |
Compositions that include combinations of agents that inhibit carbohydrate degradation, decrease formation or severity of intestinal gas, and/or modulate insulin signalling or blood glucose levels are described. Methods of administering ...
|
|
WO/2007/028812 |
The invention relates to the CGRP antagonists of general formula (I) in which R1, R2 and R3 have the definitions given in claim 1, the tautomers, isomers, diastereomers, enantiomers, anomers, hydrates, mixtures, salts, and the hydrates o...
|
|
WO/2007/028812 |
The invention relates to the CGRP antagonists of general formula (I) in which R1, R2 and R3 have the definitions given in claim 1, the tautomers, isomers, diastereomers, enantiomers, anomers, hydrates, mixtures, salts, and the hydrates o...
|
|
WO/2007/026675 |
Discloses is a process for producing α-D-glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O
-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono-Î
²-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]- or 1-(...
|
|
WO/2007/028012 |
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
|
WO/2007/028012 |
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
|
WO/2007/028050 |
Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhib...
|
|
WO/2007/023583 |
To synthesize a glycolipid derivative typified by GGPL-III, it is required to efficiently synthesize an intermediate in synthesizing the glycolipid derivative represented by the general formula (VIII). For this purpose, it is needed to c...
|
|
WO/2007/020795 |
Gallic acid derivatives represented by the general formula (1): [wherein R1 is hydrogen, alkali metal, alkaline earth metal, transition metal, substituted or unsubstituted ammonium, or alkyl or alkenyl having 1 to 22 carbon atoms; and R2...
|
|
WO/2007/021900 |
Disclosed are compositions for the treatment of anorectal disorders comprising at least one analgesic, at least one anti-inflammatory agent, antibiotic, and optionally but preferably hyaluronic acid, in amounts and under conditions effec...
|
|
WO/2007/014894 |
Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives of the general Formula (I) where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers ...
|
|
WO/2007/014894 |
Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives of the general Formula (I) where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers ...
|
|
WO/2007/016455 |
Disclosed are compositions and methods related to aminoglycoside dimers aminoglycoside conjugates, and their uses.
|
|
WO/2007/013522 |
[PROBLEMS] To provide a process for producing a glycolipid-containing Simon potato extract or a glycosphingolipid from a Simon potato for the purpose of providing an alternative to a livestock brain ganglioside which is free from the ris...
|
|
WO/2007/009637 |
The invention relates to the objects which are characterised in the patent claims, that is, metal complexes which contain perfluoroalkyl having N-alkyl groups of general formula (I), to a method for the production thereof and to the use ...
|
|
WO/2007/009772 |
The present invention relates to 3-demethoxy-3-aminothiocolchicine glycosyl derivatives of general formula (I) in which R is hydrogen, methyl or hydroxymethyl. The compounds of formula (I) have myorelaxant and anti-inflammatory activity.
|
|
WO/2007/009637 |
The invention relates to the objects which are characterised in the patent claims, that is, metal complexes which contain perfluoroalkyl having N-alkyl groups of general formula (I), to a method for the production thereof and to the use ...
|
|
WO/2007/006152 |
A buckwheat extract comprising at least myo-inositol, D-chiro-inositol, a fagopyritol, one MAPK-stimulating compound, and one glucose-uptake inhibiting compound. A substantially pure glucose-uptake inhibiting compound selected from a buc...
|
|
WO/2007/004705 |
A glycolipid derivative represented by the formula (I): (I) wherein R1 represents an aldopyranaose residue, R2 represents a hydrogen atom or a hydroxyl group, A represents -CH2-,-CH(OH)-CH2- or -CH=CHCH2-, Z represents -O- or -CH2-, and ...
|
|
WO/2007/003236 |
The method according to the invention comprises using as glycosyl donors high purity 2- deoxy-2-iodo derivatives of sugars of a defined configuration of C-2 carbon with O-alkyl, S- alkyl, O-aryl, S-aryl, O-heteroaryl, S-heteroaryl, O-acy...
|
|
WO/2007/000967 |
A remedy for cerebral infarction which contains glycyrrhizin and/or a pharmaceutically acceptable salt thereof as the active ingredient. As the pharmaceutically acceptable salt, use may be appropriately made of glycyrrhizin ammonium salt...
|
|
WO/2006/136933 |
A composition for the treatment and/or prevention of attacks by biological agents characterised in that it comprises at least: a modulator means; a by-product of Brassicaceae seeds; water.
|
|
WO/2006/136933 |
A composition for the treatment and/or prevention of attacks by biological agents characterised in that it comprises at least: a modulator means; a by-product of Brassicaceae seeds; water.
|
|
WO/2006/136429 |
The present invention relates to compounds of the formula (I); wherein R1 Js H, CH3 or OCH3; R3 = H, OH, CH3, OCH3, O-glucose or benzoyloxy; R4 = H; R5 = H or OH; R6 = H or OCH3; R7 = H, CH3, OCH3, cinnamoyloxy or (3,4,5-trimethoxy)-benz...
|
|
WO/2006/134352 |
The present invention relates to methods of preparing anthocyanins, and methods of preparing precursors of anthocyanins. The methods utilise a coupling reaction between a sugar and a suitable electrophilic precursor to form Eastern half ...
|
|
WO/2006/135083 |
Disclosed are a pharmaceutical for the prevention or treatment of visceral fat syndrome and a beverage/food for the prevention or amelioration of the disease. A prophylactic or therapeutic agent for visceral fat syndrome comprising luteo...
|
|
WO/2006/135084 |
Disclosed are a pharmaceutical for the prevention or treatment of steatohepatitis, particularly non-alcoholic steatohepatitis or fatty liver and a beverage/food for the prevention or amelioration of the disease. A prophylactic or therape...
|
|
WO/2006/133447 |
Described are novel crystalline pivaloyl furanoses and methods of crystallizing the pivaloyl furanoses. These compounds are useful as intermediates in the synthesis of compounds such as the deoxyjirimycins and nojirimycins and are partic...
|
|
WO/2006/128738 |
The invention relates to a composition for depigmenting the skin comprising a compound of formula (I) : in which: - S represents a monosaccharide or a polysaccharide containing up to 20 sugar units; - the bond S-CH2 being a C-glycoside b...
|
|
WO/2006/129075 |
The present invention provides processes for the production of polysaccharides containing the L-iduronate subunit, for example, heparin-type polysaccharides. New intermediate compounds and processes developed during the production of sai...
|
|
WO/2006/124720 |
Daunorubicin ("DNR") compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers.
|
|
WO/2006/124012 |
The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions an...
|
|
WO/2006/123558 |
It is intended to enable the synthesis of a saccharide derivative (for example, a polysaccharide, a glycolipid, a sugar amino acid, etc.) designed depending on the purpose at a low cost and a high yield by the phase dissolution/phase sep...
|
|
WO/2006/124012 |
The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions an...
|
|
WO/2006/120208 |
The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 and R3 are defined according to claim 1. Furthermore this inventions relates to intermediates obtained in these processes.
|
|
WO/2006/122296 |
Described herein are novel cerebroside compounds, designated as Turbostatin 1, Turbostatin 2, Turbostatin 3, and Turbostatin 4. These compounds were extracted and isolated from the marine mollusk Turbo stenogyrus, and their structures el...
|
|
WO/2006/120576 |
An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit ...
|
|
WO/2006/120576 |
An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit ...
|
|
WO/2006/121861 |
The invention relates to a chemical genus of 4-biphenyl-1-phenylazetidin-2-ones useful in the treatment of hypercholesterolemia and other disorders. The compounds have the general formula (I). Pharmaceutical compositions and methods for ...
|
|
WO/2006/119402 |
Compounds of the formula: (I) are described, along with pharmaceutical compositions containing these compounds, and methods of using the compounds to prevent and to treat cancer in mammals, including humans.
|
|
WO/2006/119402 |
Compounds of the formula: (I) are described, along with pharmaceutical compositions containing these compounds, and methods of using the compounds to prevent and to treat cancer in mammals, including humans.
|
|
WO/2006/115312 |
The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as a plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, can be effectively used in delivering ...
|
|
WO/2006/111616 |
The invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus. The in...
|
